Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

Mary Gleeson, Nicholas Counsell, David Cunningham, Eliza Hawkes, Anthony Lawrie, Andrew Jack, Paul Smith, Christopher Pocock, MD PhD, Kirit M. Ardeshna, MB BChir, John Radford, MD FRCP, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, MD, David C. Linch

Blood (2018) 132 (Supplement 1): 2956.

https://doi.org/10.1182/blood-2018-99-111824

Published: 2018

Journal Articles

Similarity Search Methods As an Alternative to Sub-Type Characterisation in Aggressive Lymphomas

Chulin Sha, PhD, Sharon Barrans, PhD, Andrew Jack, Cathy H Burton, Alexandra Smith, PhD, Eve Roman, Dan Painter, Simon Crouch, PhD, Reuben M Tooze, PhD FRCP, Matthew Care, PhD, David R Westhead, PhD

Blood (2016) 128 (22): 3052.

https://doi.org/10.1182/blood.V128.22.3052.3052

Published: 2016

Journal Articles

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Blood (2016) 128 (22): 1746.

https://doi.org/10.1182/blood.V128.22.1746.1746

Published: 2016

Journal Articles

Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial

Andrea Kühnl, MD, Ridwan Shaikh, David Cunningham, Sharon L Barrans, Cathy H Burton, Andrew Jack, Mary Gleeson, Nicholas Counsell, Paul Smith, Oliver Schofield, David C. Linch, FRCP, Michael Hubank, PhD

Blood (2016) 128 (22): 1747.

https://doi.org/10.1182/blood.V128.22.1747.1747

Published: 2016

Journal Articles

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

Ruth Mary de Tute, PhD FRCPath, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Christopher T Manbridge, Josh Caddy, Keith Pugh, PhD, Peter W.M. Johnson, FRCP, Andrew J Davies, MRCP, Andrew Jack, PhD MB

Blood (2015) 126 (23): 2669.

https://doi.org/10.1182/blood.V126.23.2669.2669

Published: 2015

Journal Articles

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Andrew J Davies, MRCP PhD, Josh Caddy, Tom Maishman, Sharon Barrans, PhD, Christoph Mamot, MD, Matthew Care, PhD, Christopher Pocock, Louise Stanton, PhD, Debbie Hamid, Keith Pugh, PhD, Andrew McMillan, PhD, Paul Fields, MDPhD, Anton Kruger, Andrew Jack, PhD MB, Peter W. M. Johnson, FRCP

Blood (2015) 126 (23): 812.

https://doi.org/10.1182/blood.V126.23.812.812

Published: 2015

Journal Articles

Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)

Barrans Sharon, PhD, Andrew J Davies, MRCP, Ming Wang, Ming-Qing Du, MB, PhD, Christoph Mamot, MD, Keith Pugh, PhD, Josh Caddy, Matthew A Care, PhD, Jan Taylor, Reuben M Tooze, PhD FRCP, Tom Maishman, Louise Stanton, PhD, Debbie Hamid, Andrew McMillan, PhD, Paul Fields, MD PhD, Andrew Jack, PhD MB, Peter Johnson, MD

Blood (2015) 126 (23): 331.

https://doi.org/10.1182/blood.V126.23.331.331

Published: 2015

Journal Articles

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Matthew A Care, PhD, Stephen M Thirdborough, PhD, Andrew J Davies, MRCP PhD, Peter W.M. Johnson, FRCP, Andrew Jack, PhD MB, Sharon Barrans, PhD, David R Westhead, PhD, Mark S Cragg, PhD, Reuben M Tooze, PhD FRCP, Stephen A Beers, PhD

Blood (2015) 126 (23): 2663.

https://doi.org/10.1182/blood.V126.23.2663.2663

Published: 2015

Journal Articles

Early Diagnosis of Myelodysplastic Syndromes Can be Improved By Deep Sequencing and Array Based Cytogenetics

Catherine Cargo, MB FRCPath, Nicola Rowbotham, PhD, Paul Evans, PhD, Sharon Barrans, PhD, Simon Crouch, PhD, Andrew Jack, PhD

Blood (2014) 124 (21): 167.

https://doi.org/10.1182/blood.V124.21.167.167

Published: 2014

Journal Articles

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Mary Gleeson, FRCPath, David Cunningham, FMedSci, Eliza A Hawkes, MD, Wendi Qian, PhD, Paul Smith, MSc, Nick Chadwick, Paul Mouncey, MSc, Andrew Jack, PhD, Christopher Pocock, MD PhD, Kirit M Ardeshna, MD FRCPath, John Radford, Andrew McMillan, PhD, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter W.M. Johnson, FRCP, Joanna Gambell, BSc, David C Linch, FMedSci

Blood (2014) 124 (21): 1723.

https://doi.org/10.1182/blood.V124.21.1723.1723

Published: 2014

Journal Articles

Detection of BCL2 Gene Rearrangements in the Reed-Sternberg Cells of Composite Lymphomas or Newly Diagnosed Hodgkin Lymphoma in Patients with a Previous Diagnosis of Follicular Lymphoma

Sheila J M O'Connor, PhD, Kathryn Turner, MSc, Catherine H Burton, MBBChir, MD MRCP, FRCPath, Andrew Jack, PhD

Blood (2014) 124 (21): 137.

https://doi.org/10.1182/blood.V124.21.137.137

Published: 2014

Journal Articles

Bone Marrow Staging For Lymphoma: A Re-Evaluation Of Clinical Utility

Andrew Jack, PhD, Daniel Painter, BSc, Alexandra Smith, PhD, Eve Roman, PhD, Ruth M de Tute, MSc, Russell Patmore, MD

Blood (2013) 122 (21): 4278.

https://doi.org/10.1182/blood.V122.21.4278.4278

Published: 2013

Journal Articles

Skeletal-Related Events In Myeloma: A Population-Based Study

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Bagguley Timothy, MSc, Alexandra Smith, PhD, Han-I Wang, PhD, Debra Howell, PhD, Hazem A Sayala, MBChB, MRCP, Gordon Cook, MD, PhD, Andrew Jack, PhD, Russell Patmore, MD, Eve Roman, PhD

Blood (2013) 122 (21): 3158.

https://doi.org/10.1182/blood.V122.21.3158.3158

Published: 2013

Journal Articles

Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour

Ruth M de Tute, MSc, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Peter W.M. Johnson, MD, FRCP, Andrew J Davies, MRCP, PhD, Andrew Jack, PhD

Blood (2013) 122 (21): 3013.

https://doi.org/10.1182/blood.V122.21.3013.3013

Published: 2013

Journal Articles

Social Inequality Is An Important Risk Factor For Death From Chronic Myeloid Leukaemia: Findings From a UK Population-Based Cohort

Alexandra Smith, PhD, Eve Roman, PhD, Daniel Painter, BSc, Debra Howell, PhD, Graeme Smith, MD, Paul Evans, Russell Patmore, MD, Andrew Jack, PhD

Blood (2013) 122 (21): 4036.

https://doi.org/10.1182/blood.V122.21.4036.4036

Published: 2013

Journal Articles

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Andrew McMillan, FRCP, FRCPath, PhD, Kirit M Ardeshna, FRCPath, Jo Gambell, Andrew Jack, PhD, Amy Kirkwood, Anthony Laurie, Silvia Montoto, MD, Shankaranarayana Paneesha, MD, Simon Rule, MD, Russell Patmore, MD, Ruth Pettengell, Humra Shah, Paul Smith, David Linch, FMedSci

Blood (2013) 122 (21): 4348.

https://doi.org/10.1182/blood.V122.21.4348.4348

Published: 2013

Journal Articles

Prognostic Effect Of More Than 1 Extranodal Site Of Disease For Patients With Diffuse Large B Cell Lymphoma (DLBCL) In The Rituximab Era: Results From The UK NCRI R-CHOP 14 Versus 21 Trial

Mary Gleeson, FRCPath, Wendi Qian, PhD, David Cunningham, FMedSci, Eliza Hawkes, FRACP, Andrew Jack, PhD, Paul Smith, MSc, Paul Mouncey, MSc, Christopher Pocock, PhD, Kirit M Ardeshna, FRCPath, John Radford, MD, Andrew McMillan, FRCPath, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter Johnson, FRCP, Joanna Gambell, BSc, David Linch, FMedSci

Blood (2013) 122 (21): 4268.

https://doi.org/10.1182/blood.V122.21.4268.4268

Published: 2013

Journal Articles

Development Of A Cross Platform, 2-Way Gene Expression Classifier To Distinguish Burkitt Lymphoma From DLBCL, and Assessment Of The Potential Impact Of Its Use In Treatment Decision Making

Sharon Barrans, PhD, Sha Chulin, Alex Smith, Simon Crouch, MA PhD, Lisa Worrillow, PhD, Eve Roman, PhD, David Westhead, PhD, Andrew Jack, PhD

Blood (2013) 122 (21): 74.

https://doi.org/10.1182/blood.V122.21.74.74

Published: 2013

Journal Articles

The Prognosis Of Transformed Follicular Lymphoma Is Determined By Prior Exposure To Chemotherapy

Andrew Jack, PhD, Alexandra Smith, PhD, Ruth de Tute, Daniel Painter, BSc, Eve Roman, PhD, Russell Patmore, MD

Blood (2013) 122 (21): 78.

https://doi.org/10.1182/blood.V122.21.78.78

Published: 2013

NARROW

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

Similarity Search Methods As an Alternative to Sub-Type Characterisation in Aggressive Lymphomas

The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial

Genome-Wide Methylation Analysis of Patients with Diffuse Large B Cell Lymphoma Treated on the UK NCRI R-CHOP 14 Vs 21 Trial

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Early Diagnosis of Myelodysplastic Syndromes Can be Improved By Deep Sequencing and Array Based Cytogenetics

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Detection of BCL2 Gene Rearrangements in the Reed-Sternberg Cells of Composite Lymphomas or Newly Diagnosed Hodgkin Lymphoma in Patients with a Previous Diagnosis of Follicular Lymphoma

Bone Marrow Staging For Lymphoma: A Re-Evaluation Of Clinical Utility

Skeletal-Related Events In Myeloma: A Population-Based Study

Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour

Social Inequality Is An Important Risk Factor For Death From Chronic Myeloid Leukaemia: Findings From a UK Population-Based Cohort

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Prognostic Effect Of More Than 1 Extranodal Site Of Disease For Patients With Diffuse Large B Cell Lymphoma (DLBCL) In The Rituximab Era: Results From The UK NCRI R-CHOP 14 Versus 21 Trial

Development Of A Cross Platform, 2-Way Gene Expression Classifier To Distinguish Burkitt Lymphoma From DLBCL, and Assessment Of The Potential Impact Of Its Use In Treatment Decision Making

The Prognosis Of Transformed Follicular Lymphoma Is Determined By Prior Exposure To Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only